<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309918</url>
  </required_header>
  <id_info>
    <org_study_id>HepNet-aHCV-IV</org_study_id>
    <secondary_id>2013-001081-42</secondary_id>
    <nct_id>NCT02309918</nct_id>
  </id_info>
  <brief_title>HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection</brief_title>
  <official_title>Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HepNet Study House, German Liverfoundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Clinical Trial Center GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HepNet Study House, German Liverfoundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm, multicenter, pilot-study to compare the efficacy and
      safety of LDV/SOF fixed dose combination (FDC) in subjects with acute genotype 1 HCV
      infection. A total of 20 subjects will be assigned to receive LDV/SOF FDC tablet (LDV 90
      mg/SOF 400 mg/) once daily for 6 weeks.Patients will be followed up for 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment with ledipasvir (LDV)/sofosbuvir (SOF) FDC (proportion of subjects with sustained viral response (HCV RNA &lt; LLOQ TND) using COBAS TaqMan Realtime PCR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the efficacy of treatment with ledipasvir (LDV)/sofosbuvir (SOF) FDC for 6 weeks in patients with acute genotype 1 HCV infection as measured by the proportion of subjects with sustained viral response (HCV RNA &lt; LLOQ TND) 12 weeks after discontinuation of therapy (SVR 12) using COBAS TaqMan Realtime PCR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of LDV/SOF FDC-containing regimens (frequency of AEs and SAEs)</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>To evaluate the safety and tolerability of LDV/SOF FDC-containing regimens administered for up to 6 weeks in patients with acute genotype 1 HCV infection as measured by the frequency of AEs and SAEs assessed at end of treatment, 12 and 24 weeks after end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of response (proportion of subjects with sustained viral response (HCV RNA &lt; LLOQ TND)</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>To determine the durability of response after discontinuation of therapy as measured by the proportion of subjects with sustained viral response (HCV RNA &lt; LLOQ TND) 24 weeks after discontinuation of therapy (SVR 24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of circulating HCV RNA (mean viral load)</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>To evaluate the kinetics of circulating HCV RNA measured as mean viral load during treatment (Baseline, week 2,4,6) and after treatment discontinuation (Follow up week 4, 12, 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of viral resistance to LDV/SOF FDC</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>To evaluate the emergence of viral resistance to LDV/SOF FDC during treatment and after treatment discontinuation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HCV-specific T cell responses</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>To assess any relationship between HCV-specific T cell responses and treatment efficacy</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between NK cell phenotype and function and treatment efficacy</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>To assess any relationship between NK cell phenotype and function and treatment efficacy</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between circulating serum chemokines and treatment efficacy and safety</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>To assess any relationship between circulating serum chemokines and treatment efficacy and safety</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Hepatitis C</condition>
  <arm_group>
    <arm_group_label>LDV/SOF FDC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF FDC</intervention_name>
    <description>Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily</description>
    <arm_group_label>LDV/SOF FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide written informed consent

          2. Male or female, age ≥ 18 years

          3. HCV RNA ≥ 103 IU/mL at Screening

          4. Confirmation of acute genotype 1 HCV infection documented by either:

             documented seroconversion to HCV antibody positivity within the 4 months preceding
             screening or known or suspected exposure to HCV within the 4 months preceding
             screening with 10 times elevated serum ALT Level at screening or 4 weeks preceding
             screening without evidence of confounding liver disorders

          5. If the patient visits a physician due to symptoms of acute HCV, no greater than a 12
             week interval may have elapsed between the time of the visit and screening

          6. Non-cirrhotic. Absence of cirrhosis will be determined based on clinical parameters or
             ultrasound

          7. Body mass index (BMI) ≥ 18 kg/m2

          8. Screening ECG without clinically significant abnormalities

          9. Subjects must have the following laboratory parameters at screening:

               1. Hemoglobin ≥ 10 g/dL

               2. Platelets ≥ 90,000/µL

               3. INR ≤1.5 x ULN unless subject has known hemophilia or is stable on an
                  anticoagulant regimen affecting INR

               4. Albumin ≥ 3 g/dL

               5. HbA1c ≤ 10%

               6. Creatinine clearance (CLcr) ≥ 60 mL/min, as calculated by the Cockcroft- Gault
                  equation

         10. Subject has not been treated with any investigational drug or device within 42 days of
             the Screening visit

         11. A negative serum pregnancy test is required for female subjects (unless surgically
             sterile or women ≥ 54 years of age with cessation for 24 ≥ months of previously
             occurring menses).

             Complete abstinence from intercourse. Periodic abstinence (e.g., calendar, ovulation,
             symptothermal, post-ovulation methods) is not permitted.

             Or

             Consistent and correct use of 1 of the following methods of birth control listed
             below, in addition to a male partner who correctly uses a condom, from the date of
             Screening until 30 days after last dose of study drug:

               -  intrauterine device (IUD) with a failure rate of &lt; 1% per year

               -  female barrier method: cervical cap or diaphragm with spermicidal agent

               -  tubal sterilization

               -  vasectomy in male partner

               -  hormone-containing contraceptive:

               -  implants of levonorgestrel

               -  injectable progesterone

               -  oral contraceptives (either combined or progesterone only)

               -  contraceptive vaginal ring

               -  transdermal contraceptive patch

         12. Male subjects must agree to refrain from sperm donation from the day of screening and
             for at least 90 days after the last dose of study drug.

         13. Subject must be of generally good health as determined by the Investigator.

         14. Subject must be able to comply with the dosing instructions for study drug
             administration and be able to complete the study schedule of assessments.

        Exclusion Criteria:

          1. Clinically-significant illness (other than HCV) or any other major medical disorder
             that, in the opinion of the investigator, may interfere with subject treatment,
             assessment or compliance with the protocol; subjects currently under evaluation for a
             potentially clinically-significant illness (other than HCV) are also excluded.

          2. Gastrointestinal disorder or post operative condition that could interfere with the
             absorption of the study drug (for example, gastric bypass or severe ulcerative
             colitis).

          3. Difficulty with blood collection and/or poor venous access for the purposes of
             phlebotomy.

          4. Clinical hepatic decompensation (i.e., clinical ascites, encephalopathy or variceal
             hemorrhage).

          5. Solid organ transplantation.

          6. Significant pulmonary disease or significant cardiac disease.

          7. Psychiatric hospitalization, suicide attempt, and/or a period of disability as a
             result of their psychiatric illness within the last 2 years. Subjects with psychiatric
             illness that is well-controlled on a stable treatment regimen for at least 12 months
             prior to screening or has not required medication in the last 12 months may be
             included.

          8. Malignancy within 5 years prior to screening, with the exception of specific cancers
             that are entirely cured by surgical resection (basal cell skin cancer, etc). Subjects
             under evaluation for possible malignancy are not eligible.

          9. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

         10. Any prior treatment for HCV infection including prior exposure to any inhibitor of the
             NS5B and NS5A.

         11. Pregnant or nursing female or male with pregnant female partner

         12. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, autoimmune
             hepatitis, alcoholic liver disease, Wilson's disease, α1 antitrypsin deficiency,
             cholangitis)

         13. Infection with hepatitis B virus (HBV; defined as HBsAg-positive) or human
             immunodeficiency virus (HIV)

         14. Chronic use of systemically administered immunosuppressive agents (e.g., prednisone
             equivalent &gt; 10 mg/day)

         15. Clinically-relevant drug or alcohol abuse within 12 months of screening including any
             uncontrolled drug use within 6 months of screening. A positive drug screen will
             exclude subjects unless it can be explained by a prescribed medication; the diagnosis
             and prescription must be approved by the investigator. Uncontrolled users of
             intravenous drugs will not be permitted to enroll in the study.

         16. Donation or loss of more than 400 ml blood within 2 months prior to Baseline/Day 1

         17. Use of any prohibited concomitant medications within 21 days of the Baseline/Day 1
             visit, this washout period does not apply to proton pump inhibitors, which can be
             taken up to 7 days before Day 1.

         18. Known hypersensitivity to LDV, SOF or formulation excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P. Manns, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MHH, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Carl-Neuberg-Str. 1, 30625 Hannover, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>• Charite, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>• Universitätsklinikum Essen, Klinik für Gastroenterologie und Hepatologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Medizinische Klinik 1</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik für Innere Medizin II, Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifi, Institut für Interdisziplinäre Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Gastroenterologie, Infektionen, Vergiftungen</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis Herne</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Klinik für Innere Medizin II - Gastroenterologie und Endokrinologie</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Innere Medizin 1, Gastroenterologie, Hepatologie, Ernährungs- und Altersmedizin</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Gastroenterologie und Rheumatologie</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oberberg City München</name>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU-München, II. Medizinische Klinik und Poliklinik (Gastroenterologie)</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Offenburg GmbH, St. Josefklinik, Ambulante Gastroenterologie</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Innere Medizin I, Hepatologie, Gastroenterologie, Infektiologie</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg,Medizinische Klinik und Poliklinik II, Zentrum Innere Medizin</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28.</citation>
    <PMID>28029529</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute HCV Genotype 1 Infection</keyword>
  <keyword>HCV RNA</keyword>
  <keyword>LDV/SOF FDC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

